Aurisco Pharmaceutical's Peptide and Oligonucleotide Ventures Fuel Future Growth

In Aurisco Pharmaceutical's carefully planned and strategic roadmap, the peptide and oligonucleotide businesses have been assigned a crucial role, viewed as the key engines driving the company's future growth. In the peptide business domain, Aurisco Pharmaceutical's innovative momentum remains unabated, with its newly constructed semaglutide API production line expected to commence pilot sales in the second half of 2024. This project not only demonstrates the company's technological prowess but also its deep exploration of market potential. Leveraging its unique semi-fermentation production technology, Aurisco Pharmaceutical is poised to achieve large-scale capacity release in 2025-2026, significantly boosting the company's gross profit margins. According to internal projections, this business unit is expected to generate over 1.1 billion in revenue, showcasing its powerful profit potential.

In the oligonucleotide business, Aurisco Pharmaceutical, through its Aurisco Pharmaceutical Biotech subsidiary in Shanghai, has successfully entered the small nucleic acid drug CRO/CDMO service market. The company has already achieved the commercialization of nusinersen, maintaining a sound profit-loss balance and demonstrating its competitive advantages in this emerging field. With the continued increase in global investment in small nucleic acid drug R&D and growing market demand, Aurisco Pharmaceutical's strategic moves in the oligonucleotide business will provide a steady stream of impetus for the company's long-term performance growth.

Aurisco Pharmaceutical is gradually building a solid profitability foundation through a diversified development strategy encompassing formulations, peptides, and oligonucleotides. This diversified business structure not only helps the company withstand the risks associated with market fluctuations but also enables it to maintain a competitive edge in the constantly evolving market environment, achieving sustainable long-term growth. Aurisco Pharmaceutical's strategic transformation undoubtedly demonstrates its keen insight into industry trends and its unwavering confidence in future development.